| Date | Title | Description |
| 03.04.2026 | TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data
Collaboration will expand Regeneron's world-leading genomic and prot... |
| 27.03.2026 | AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed | Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former s... |
| 20.03.2026 | How CNBC Cures is bringing rare disease stories to a national audience | “Squawk Box” co-host Becky Quick launched CNBC Cures in January, the network’s initiative to raise awareness for rare diseases.
Since its launch, CNBC has rolled out a weekly CNBC Cures newsletter, a podcast, a live event, and has featured ... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 18.02.2026 | Avantos Raises $25M in Series A Funding | Avantos, a NYC-based provider of an artificial intelligence (“AI”)-native operating system, raised $25M in Series A funding.
The round was led by Bessemer Venture Partners with participation from new strategic investors, including The Guard... |
| 18.02.2026 | Armistice Capital Among Funds With Exposure to Regeneron as Biopharma Focus Shifts Back to Late-Stage Execution | x
Please enable JavaScript
Video Player is loading.Play Video
Play
Unmute
1xPlayback Rate
2x1.5x1x, selected0.5x
Captions
captions off, selectedAmerican English CaptionsWatch on Open.Video
ShareFullscreen
Now Playing
Up NextGovernmental Fun... |
| 08.02.2026 | Almost 4,000 girls to attend 12th annual I Wish Festival at the RDS | Almost 4,000 female teenage students from across the island are expected to attend the 12th annual I Wish Festival at the RDS, Dublin.
The event is focused on promoting STEM subjects, science, technology, engineering, and mathematics to gir... |
| 24.01.2026 | BrightInsight Secures $13M: AI Fuels Medication Adherence Revolution | BrightInsight secured $13 million in new funding. This capital accelerates AI-driven medication adherence solutions. It will scale global patient support programs. Top investors, including Mayo Clinic, backed the digital health leader. The ... |
| 22.01.2026 | Think Bioscience Secures $55M Series A for 'Undruggable' Target Therapies | Think Bioscience, a Boulder, CO-based drug discovery innovator, closed an oversubscribed $55 million Series A funding round. This substantial investment accelerates R&D and operational expansion. The firm pioneers small molecule therape... |
| 21.01.2026 | BrightInsight: $13 Million Closed To Expand AI-Enabled Medication Adherence Platform | BrightInsight has raised $13 million in funding to accelerate the development of its AI-enabled medication persistence and adherence solutions and scale patient support programs globally. The San Jose-based digital health company said the r... |
| 21.01.2026 | Think Bioscience: $55 Million Raised For Developing Small-Molecule Drugs | Think Bioscience, a Boulder, Colorado-based biotechnology company developing small-molecule drugs against historically difficult targets, has raised $55 million in an oversubscribed Series A financing to advance its internal pipeline of fir... |
| 20.01.2026 | Think Bioscience Raises $55M in Series A Funding | Think Bioscience, a Boulder, CO-based privately held small molecule drug discovery company, raised $55M in Series A funding.
The round was led byRegeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from... |
| 20.01.2026 | BrightInsight Raises $13M in Funding | BrightInsight, a San Jose, CA-based company which specializes in digital health solutions, raised $13M in funding.
Backers included Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners.
The company intends... |
| 02.01.2026 | Vyriad Raises Final $25M Series B Tranche | Vyriad, Inc., a Rochester, Minn.-based clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, closed the $25M final tranche to its Series B financing, bringing the total Series B ro... |
| 28.12.2025 | Atavistik Bio Secures $120 Million: Advancing Precision Therapies for HHT and MPNs | Atavistik Bio secured $120 million in Series B funding. This substantial capital will advance two crucial therapeutic programs. An oral AKT1-selective inhibitor targets Hereditary Hemorrhagic Telangiectasia (HHT). A JAK2 V617F mutant-select... |
| 27.12.2025 | Atavistik Bio: $120 Million Series B Raised To Advance Selective Allosteric Small-Molecule Programs In HHT And MPNs | Atavistik Bio announced it raised a $120 million Series B financing to push two selective allosteric small-molecule programs into clinical proof-of-concept studies: an oral, AKT1-selective allosteric inhibitor for hereditary hemorrhagic tel... |
| 25.12.2025 | Vyriad Revolutionizes Cancer Care: $85M Fuels "One-Shot" In Vivo CAR T for Multiple Myeloma | Vyriad closes an $85M Series B round. This fuels VV169, its groundbreaking in vivo CAR T-cell therapy. VV169 targets multiple myeloma, delivering a curative genetic payload via a single intravenous injection. This revolutionary approach byp... |
| 23.12.2025 | Vyriad: Final $25 Million Series B Tranche Closed To Advance In Vivo CAR T Candidate Into Clinic | Vyriad, a Rochester, Minnesota-based clinical-stage biotechnology company developing targeted genetic therapies, said it has closed a $25 million final tranche of its Series B financing, bringing the round’s total to $85 million. The compan... |
| 21.12.2025 | Atavistik Bio Raises $120M in Series B Financing | Atavistik Bio, a Cambridge, MA-based developer of selective allosteric small molecule therapeutics, raised $120m in Series B financing.
The round was led by Nextech Invest and The Column Group with participation from Lux Capital and new inv... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 11.12.2025 | Triana Biomedicines: $120 Million Series B Secured To Advance Molecular Glue Degrader Pipeline | Triana Biomedicines has closed an oversubscribed $120 million Series B financing round that will accelerate development of its molecular glue degrader platform and advance its lead program, TRI-611, toward clinical proof-of-concept in patie... |
| 12.11.2025 | AI-Driven Biotech Iambic Secures Over $100M for Drug Discovery | Iambic, a San Diego AI-driven biotech, secured over $100M in funding. This capital fuels its advanced AI drug discovery platform and expanding clinical pipeline. The company rapidly advances novel therapies, like IAM1363, showing strong ant... |
| 11.11.2025 | Iambic Raises Over $100M in Funding | Iambic, a San Diego, CA-based clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, raised over $100M in funding.
Backers included Abingworth, Alexandria Ventur... |
| 31.10.2025 | JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential | SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an A... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 22.10.2025 | Tezspire Approved in EU for CRSwNP | Tezspire Approved in EU for CRSwNP
Wed, Oct 22, 2025 08:00 CET Report this content
22 October 2025
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
Approval based on WAYPOINT Phase III results demonstrating reduced n... |
| 20.10.2025 | US FDA Approves Tezspire in CRSwNP | US FDA Approves Tezspire in CRSwNP
Mon, Oct 20, 2025 08:05 CET Report this content
20 October 2025
Tezspire approved in the US for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease charac... |
| 10.10.2025 | Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept) | EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR)
Celltrion... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 22.09.2025 | Tezspire Recommended for Approval in EU for CRSwNP | Tezspire Recommended for Approval in EU for CRSwNP
Mon, Sep 22, 2025 08:34 CET Report this content
22 September 2025
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Recommendation based on WA... |
| 21.08.2025 | A new pharma factory shows how hard it could be for drugmakers to outrun Trump’s tariffs | Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers.
The Holly Springs, North Carolina, site is five years and $3.2 billion in the m... |
| 21.08.2025 | J&J инвестирует $2 млрд для расширения производства в США на фоне угроз тарифов на лекарства | Крупные фармацевтические компании, включая Eli Lilly и AstraZeneca, также заявили о планах вложить миллиарды долларов в развитие своих производственных мощностей в США в ответ на инициативы Трампа, включая угрозы тарифов. Ранее в этом месяц... |
| 12.08.2025 | Prevent Blindness Announces New Diabetes + the Eyes Advisory Committee | Prevent Blindness establishes new Diabetes + the Eyes Advisory Committee, bringing together patients and professionals to address one of the leading causes of blindness in the United States.
New Prevent Blindness "Diabetes + the Eyes&q... |
| 07.08.2025 | Strand Therapeutics Raises $153M in Series B Financing | Strand Therapeutics, a Boston, MA-based company which specializes in new mRNA-based therapeutics, raised $153M in Series B funding.
The round was led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Grou... |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 23.07.2025 | AI start-up founded by Irish teenager raises $1.4m | Source, the Irish start-up founded by teenager Liam Fuller, has raised $1.4m (€1.2m) in a pre-seed funding round led by Australian venture capital outfit Square Peg.
Source is building an AI procurement platform for retail businesses that i... |
| 18.06.2025 | Data Breaches and Biotech Alliances: The Future of Health Tech in the UK and US | In the world of health tech, data is gold. But what happens when that gold is stolen? The recent fine imposed on 23andMe serves as a stark reminder of the vulnerabilities lurking in the shadows of biotech innovation. The UK’s Information Co... |
| 18.06.2025 | The Genetic Gamble: 23andMe's Resurrection and the Fluoride Debate | In the world of biotech, fortunes can shift like sand. Just look at 23andMe. Once a titan of genetic testing, it faced a steep decline, filing for Chapter 11 bankruptcy in March 2025. But now, a phoenix rises from the ashes. Anne Wojcicki, ... |
| 17.06.2025 | 23andMe handed huge fine days after rescue | Testing firm 23andMe has been fined more than £2m for failing to protect the sensitive personal and genetic data of more than 155,000 UK customers, in what regulators described as a “profoundly damaging” breach.
The UK’s Information Commiss... |
| 17.06.2025 | Regeneron declines to make higher bid for 23andMe after Wojcickis $305 million offer | - |
| 13.06.2025 | Anne Wojcicki to buy back 23andMe and its data for $305 million | Anne Wojcicki’s nonprofit will acquire substantially all of 23andMe’s assets for $305 million, the company announced Friday.
23andMe filed for Chapter 11 bankruptcy protection in March.
Last month, Regeneron announced it would purchase most... |
| 10.06.2025 | US states sue 23andMe to protect customers' private data | US states sue 23andMe to protect customers' private data
By ReutersJune 10, 20258:54 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Attendees visit the 23andMe booth at the RootsTech annual gen... |
| 07.06.2025 | Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color | Atopic dermatitis is a chronic disease that disproportionately impacts communities of color
Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients
Pati... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 04.06.2025 | Health-care stocks are due for a turnaround after a historically bad month, according to the charts | - |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 27.05.2025 | 23andMe to delist from Nasdaq, deregister with SEC | 23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the SEC.
The company filed for for Chapter 11 bankruptcy protection in March.
Regeneron Pharmaceuticals said earlier this month that it will acquir... |
| 23.05.2025 | Regeneron’s Bold Move: The Acquisition of 23andMe and Its Implications for Genetic Data | In a world where data is the new gold, Regeneron Pharmaceuticals has struck a deal that could reshape the landscape of genetic testing and data privacy. The acquisition of 23andMe, a company once celebrated for its consumer DNA testing kits... |
| 23.05.2025 | Regeneron’s Acquisition of 23andMe: A New Era for Genetic Data | The world of biotechnology is a complex web, and the recent acquisition of 23andMe by Regeneron Pharmaceuticals adds another layer to this intricate tapestry. For years, 23andMe has been a household name, known for its consumer DNA testing ... |
| 20.05.2025 | Regeneron’s Bold Move: Acquiring 23andMe Amidst Bankruptcy | In a dramatic twist of fate, Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million. This deal comes on the heels of 23andMe’s bankruptcy, a stark contrast to its once-thriving status as a pioneer in genetic testing. The acqui... |
| 20.05.2025 | D-Wave Quantum shares soar 30% as company releases latest computing system | D-Wave Quantum shares popped 30% after announcing the debut of its latest quantum computing system.
The quantum computer, known as Advantage2, is its sixth iteration and most advance system, D-Wave said.
Quantum computers promising to solve... |
| 20.05.2025 | Elon Musk commits to leading Tesla for next five years | Tesla CEO Elon Musk committed to leading the company for the next five years.
Musk spoke in an interview at Bloomberg’s Qatar Economic Forum.
Some investors have questioned Musk’s dedication to Tesla as he has been serving as a key advisor ... |
| 20.05.2025 | 23andMe Has Found a Buyer—Here’s What Might Happen to Your Genetic Data | A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+
It’s been a turbulent stretch for 23andMe, the consumer DNA testing company once famous ... |
| 19.05.2025 | 23andMe Is Selling Its Customers' Genetic Data to Drug Maker Regeneron: 'The Power of Genetics and Data' The database includes DNA samples from about 15 million people. | Genetic testing startup 23andMe, which filed for bankruptcy earlier this year, announced on Monday that it has agreed to sell the genetic data of its 15 million users, along with its core business, to drug developer Regeneron Pharmaceutical... |
| 19.05.2025 | Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million | Regeneron Pharmaceuticals is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.
The drugmaker is buying 23andMe’s Personal Genome Service, Total Health and Research Services business lines, bu... |
| 19.05.2025 | 23andMe's journey from DNA testing pioneer to bankruptcy sale | 23andMe's journey from DNA testing pioneer to bankruptcy sale
By ReutersMay 19, 202512:34 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Attendees purchase DNA kits at the 23andMe booth at the ... |
| 19.05.2025 | Biotechnology company Regeneron buying 23andMe for $256 million | Regeneron said Monday that it will comply with 23andMe’s privacy policies and applicable law, process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in ef... |
| 19.05.2025 | Drugmaker Regeneron to acquire 23andMe out of bankruptcy | Please subscribe to IBJ to decode this article.
det llbgwcndt rsdaerciota eetettnf gfe’md epaeurNi3brdhonctAis tuepmPsasuq pvso d arupa aaa faeshsaosort essniydnoct aevdngea olcaicrctotaRda eauns ii sfoin fs sMcmntr eertgn i .r ym2naurlitne... |
| 19.05.2025 | Judge calls out ‘Apple official who is personally responsible’ in Fortnite app order | Apple must work out its latest issues with Epic Games or head back to court to prove it has a legal basis for delaying the restoration of Fortnite to its iOS App Store.
Fortnite recently re-submitted its game but was blocked by Apple, Epic ... |
| 19.05.2025 | Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million | Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
By ReutersMay 19, 202512:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The Regeneron Pharmaceuticals company logo is seen... |
| 15.05.2025 | A New Dawn for COPD Treatment: Dupixent's Approval in Singapore | In a significant breakthrough for chronic obstructive pulmonary disease (COPD) patients, Singapore has approved Dupixent (dupilumab) as the first biologic treatment for this debilitating condition. This decision, announced on May 14, 2025, ... |
| 14.05.2025 | Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD | Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and hea... |
| 30.04.2025 | Appian Celebrates 2025 Innovation Award Winners | Customers Delivered Value with Process Orchestration and AI Capabilities on the Appian Platform
SYDNEY, April 30, 2025 /PRNewswire/ -- Appian (Nasdaq: APPN) today announced the 2025 Appian Innovation Awards winners at Appian World, its annu... |
| 29.04.2025 | Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more | - |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 22.04.2025 | Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines | New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region
Regeneron’s ongoing and planned i... |
| 18.04.2025 | Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) | Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo
In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic ... |
| 18.04.2025 | Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application | TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biolo... |
| 18.04.2025 | Communiqué de presse : Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée | Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée Aux États-Unis, le Dupixent est indiqué à plus de 300 000 adultes et adolescents âg... |
| 18.04.2025 | Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria | Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, th... |
| 17.04.2025 | World Hemophilia Day 2025 - April 17, 2025 - "Access for all: Women and girls bleed too" | MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women an... |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 09.04.2025 | Pharmaceutical stocks rise as Trump pauses tariffs but not for China | Some pharmaceutical stocks rose after President Donald Trump said he would pause most so-called reciprocal tariffs, temporarily easing fears about the impact of potential tariffs on pharmaceuticals .
Shares of most U.S.-based companies turn... |
| 02.04.2025 | Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma | Basal Cell Carcinoma CSR Highlights
CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients.
Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (S... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 28.03.2025 | These dividend stocks will benefit from longevity’s ‘transformational’ opportunity, UBS says | - |
| 28.03.2025 | Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) | Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils
Approval marks the first new treatment approach for COPD in more than a decade in Japan and the... |
| 28.03.2025 | Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD | Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophilsApproval ma... |
| 25.03.2025 | Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 | TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financ... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 20.03.2025 | The aging population is a $1 trillion opportunity. These stocks are the winners, says Mizuho | - |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 11.03.2025 |
Cramer’s Lightning Round: ‘We’re going to stay away from’ Sirius XM | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Crocs: ”...Crocs no, On yes.”
Sirius XM: “N... |
| 08.03.2025 | Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD | Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD Cinq fois plus d’adultes traités par Dupixent présentaient une rémission soutenue à la semaine 36, comparativem... |
| 08.03.2025 | Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD | Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Dupixent also significantly reduced oral corticosteroid and rescue m... |
| 08.03.2025 | Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD | Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease se... |
| 08.03.2025 | Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD | Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Dupixent also significantly reduced oral corticosteroid and rescue m... |
| 08.03.2025 | Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD | Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease se... |
| 06.03.2025 | The Data Revolution: Unifying for AI Readiness and Heavy-Duty Electrification | In the digital age, data is the new oil. Organizations are racing to refine it, unify it, and harness its power. A recent survey reveals that 86% of organizations are prioritizing data unification to prepare for the AI revolution. Meanwhile... |
| 06.03.2025 | The Data Dilemma: Unifying for AI Readiness in a Multi-Cloud World | In the fast-paced world of technology, data is the new oil. But like oil, it needs refining. A recent survey reveals that 86% of organizations are prioritizing data unification to prepare for the AI revolution. This is not just a trend; it’... |
| 03.03.2025 | New Survey Reveals 86% of Organizations Are Prioritizing Data Unification for AI Readiness | Survey finds a strong need for data unification, multi-cloud adoption, AI-driven transformation, and metadata control as organizations seek to maximize their data’s value
A new industry survey from Dremio finds a growing urgency for data un... |
| 28.02.2025 | Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman | SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. TD Cowen recentl... |
| 28.02.2025 | Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma | TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinio... |
| 28.02.2025 | Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman | REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disap... |